GBS Inc.

NASDAQ: GBS · Real-Time Price · USD
0.47
-0.01 (-2.25%)
At close: Oct 27, 2022, 4:00 AM

Company Description

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America.

It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva.

The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.

GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests.

The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019.

The company was incorporated in 2016 and is headquartered in New York, New York.

GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

GBS Inc.
GBS Inc. logo
Country United States
IPO Date Dec 23, 2020
Industry Medical - Devices
Sector Healthcare
Employees 12
CEO Harry Simeonidis

Contact Details

Address:
708 3rd Avenue
New York, New York
United States
Website https://gbs.inc

Stock Details

Ticker Symbol GBS
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001725430
CUSIP Number
ISIN Number US36151G1058
Employer ID 82-1512711
SIC Code 3841

Key Executives

Name Position
Dr. Stephen Constantine Boyages M.D., MBBS, Ph.D. Interim Chief Executive Officer & Chairman
Spiro Kevin Sakiris B.Bus, C.A., CA, Dip Law Chief Financial Officer
Alex Arzeno Vice President of Investor Relations
Harry Simeonidis Pres of Asia Pacific
Victoria Gavrilenko Operations Mang.

Latest SEC Filings

Date Type Title
Apr 04, 2025 SEC STAFF ACTION Filing
Apr 01, 2025 ARS Filing
Apr 01, 2025 DEF 14A Filing
Mar 31, 2025 4/A [Amend] Filing
Mar 26, 2025 8-K Current Report
Mar 25, 2025 8-K Current Report
Mar 21, 2025 8-K Current Report
Mar 14, 2025 8-K Current Report
Mar 12, 2025 8-K Current Report
Mar 11, 2025 424B5 Filing